Skip to main content
BioCentury, the Bernstein Report on BioBusiness
As published for the week of Monday, September 15, 2014


  • Cover Story: Strategy: Cancer: Cost and quality

    How cancer reimbursement reform could boost or inhibit drug use

    By Erin McCallister, Senior Editor

    Early data from the first of several U.S. experiments with cancer payment reform offer the tantalizing possibility that drug companies could actually benefit from schemes designed to reward oncologists for outcomes as well as cost reductions. However, the first pilot - published in July by UnitedHealth Group Inc. - was too small to draw firm conclusions about drug utilization. And not all the other experiments that are under way or in the planning stages include both outcome and cost metrics in their calculations of reimbursement.

    The experiments now in progress or on the drawing board take different routes to physician reimbursement reform, such as bundled payments covering drugs and services, or treatment pathways that require adherence to preferred regimens. Those differences aside, they all seek to reduce costs without sacrificing the quality of care.

    Full Article

Money Raised in 2014

Last week, the biotech industry raised $478 million, bringing to $39.4 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 billion in debt, $10 billion in follow-ons, $2.8 billion in PIPEs and other equity, $3.9 billion in IPOs, and $6 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial